Too many MedTech companies treat reimbursement as the final step after CE marking and initial commercialization. However, in practice, this is often where strategic difficulties begin.
In France, CE marking allows a medical device to be placed on the market, but it does not automatically provide market access. Therefore, navigating Medtech reimbursement in France follows a different logic, driven by health technology assessment, clinical value, hospital economics, and the organization of the healthcare system.
For many international MedTech companies, one of the first misconceptions is to see reimbursement as an administrative dossier prepared at the end of clinical development. In reality, the process is very different and requires early integration.
Medtech reimbursement in France is driven by clinical value
The French reimbursement system evaluates much more than technical device performance. Specifically, the Haute Autorité de Santé (HAS), through its CNEDiMTS committee, assesses several strategic dimensions:
- Clinical benefit: The absolute medical value of the technology.
- Care pathway: The exact place of the device in the patient care pathway.
- Target population: The precise definition of the target patient population.
- Clinical practice: A direct comparison with current clinical practice.
- Therapeutic improvement: The expected added value versus existing therapies.
In addition, one important principle is often underestimated by emerging MedTech companies: innovation is different from improvement. A device may be technologically innovative while providing limited demonstrated clinical improvement compared with current standards of care.
Consequently, this distinction has major consequences for Medtech reimbursement in France, especially regarding go-to-market sequencing, pricing expectations, and future market adoption.
Why reimbursement and go-to-market strategy should start early
Successful Medtech reimbursement in France is rarely built at the end of the process. In practice, strategic preparation should begin much earlier, particularly when addressing key operational milestones:
- When defining the clinical indication and selecting the right comparator.
- When designing the clinical development plan to fit French requirements.
- When identifying the target population and evaluating the most appropriate reimbursement pathway.
- When preparing early KOL engagement and reference centers.
- When defining the future go-to-market model.
Furthermore, several reimbursement pathways may be considered depending on the device profile and commercial strategy:
- LPPR reimbursement: Outpatient or specific device listing.
- Intra-DRG / intra-GHS funding: Integration into hospital bundles.
- PECT / PECAN mechanisms: Specific early access pathways for digital health and innovative devices.
- Forfait Innovation: Early funding conditional on evidence generation.
- Article 51: Experimental and multi-professional pathways.
Each pathway implies different expectations in terms of evidence generation, timelines, and hospital funding logic. This is why reimbursement and go-to-market should not be managed as two separate workstreams. Instead, they are two dimensions of the same market entry strategy.
A weak reimbursement strategy often creates a weak market entry
One of the most frequent strategic mistakes is to separate clinical development, reimbursement planning, and go-to-market preparation. Indeed, many companies generate clinical evidence primarily to support regulatory approval while only later considering the expectations of the French healthcare system.
However, achieving successful Medtech reimbursement in France requires much more than regulatory compliance. To illustrate, it requires demonstrating:
- Clinical relevance and clear organizational value.
- Healthcare system integration and economic legitimacy.
- Real adoption potential in everyday hospital practice.
Clearly, a weak strategic positioning at the beginning often leads to a weak reimbursement dossier at the end. And in practice, weak dossiers rarely become strong through formatting alone.
The same applies to go-to-market execution. For instance, if the first French users, reference centers, and clinical champions are not identified early, the company may struggle to create the adoption momentum needed to support future reimbursement discussions.
Go-to-market perspective: reimbursement starts in the field
In real-life hospital dynamics, reimbursement strategy is closely connected to future market adoption. Therefore, before submitting a reimbursement dossier, companies should already be asking crucial questions:
- Which physicians are likely to become early adopters?
- Which reference centers could support future diffusion?
- How will the therapy fit into existing clinical workflows?
- Will hospitals perceive sufficient medical and economic value?
- What level of training and procedural support will be required?
- Should the first phase rely on direct presence, a distributor, or a hybrid model?
Ultimately, securing Medtech reimbursement in France is not only a regulatory exercise. On the contrary, it is part of a broader ecosystem involving clinical evidence, KOL engagement, hospital economics, procedure coding, purchasing dynamics, and long-term adoption potential.
This is why these aspects should always be designed together from the very beginning. After all, the objective is not only to prepare a dossier; the objective is to create the conditions for market adoption.
Strategic takeaway
For international MedTech companies entering France, the key question is often not: “Can we submit a reimbursement dossier?”
Instead, the more strategic question is: “Are we building the right evidence, positioning, and go-to-market foundation to support long-term reimbursement and adoption in France?”
Because in the French healthcare system, reimbursement success usually starts much earlier than most companies initially expect. In fact, it almost always starts before the first French hospital uses the device.
Entering France requires more than a reimbursement dossier. Caredis helps international MedTech companies align reimbursement strategy, go-to-market execution, and hospital adoption from the earliest stages.
